Indian Stock Market News, Equity Market and Sensex Today in India | Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

Sensex Continues Downtrend; GSK Consumer Down 9%
Wed, 28 Mar 01:30 pm | Parth Parekh, TM Team

After opening the day in red, share markets in India have continued to slide and are trading below the dotted line. Sectoral indices are trading on a mixed note with stocks in the metal sector and stocks in the metal sector leading the losses.

The BSE Sensex is trading down by 175 points (down 0.5%), and the NSE Nifty is trading down by 53 points (down 0.5%). Meanwhile, the BSE Mid Cap index is trading down by 0.5%, while the BSE Small Cap index is trading down by 0.8%. The rupee is trading at 64.94 to the US$.

Lupin share price was in focus today, after it was reported that the company received a ANDA (abbreviated new drug application) approval from the United States Food & Drug Administration (USFDA) for Clobetasol Propionate Spray.

The drug is a generic version of Galderma Laboratories' Clobex Spray.

According to IQVIATM sales data, the Clobex Spray had sales of around US$ 30.5 million in the US for the twelve months ended January 2018.

Indian pharma companies catering to the US markets are breathing a sigh of relief. After being adversely affected by import bans and the suspension of new drug approvals from manufacturing facilities in the past three years, there has been a sharp pick-up in new drug approvals in FY17.

Expediting Drug Approval Process to be a Positive for Industry

However, note that USFDA alerts on Indian pharma companies have increased over the past few years. Regulators used to visit the plants every two years. Now they come every eight months. Increasing inspections have led to a total of 41 import alerts in the past eight years - 33 of them (80%) in just the last four years (2013-16). This clearly signifies increased USFDA scrutiny on Indian pharma firms. If that wasn't enough, increasing pricing pressure in the generics segment has dented realisations.

However, the recent development of USFDA expediting the drug approval process can bring some respite for Indian pharma companies. This comes as drug approvals for Indian companies have gone up 50% in the period from January to June 2017 compared to the same period last year.

--- Advertisement ---
Should You Be Afraid of the Market Crash?

Last week was a dark week for investors. Many are left wondering - what happens next?

Today, we're going to show you how not only to survive this Market Crash, but to take advantage of it using our small cap stocks recommendation service.

This is the perfect time to get rich from this proven strategy.

Our small cap service has had a superb 10-year run. And to celebrate that we are giving you the opportunity to claim 1 year access to our Small Cap service… virtually FREE!

But this unique opportunity ends on 31st March 2018.

So, you need to act fast…

Click here to learn more…

While short-term pain is expected, companies with strong R&D capabilities and compliant plants will do well over the long term. The uncertainties make it important to be stock specific in the sector. It is important to look for companies that have the competence and staying power to overcome the challenges.

At the time of writing Lupin share price was trading up by 0.8%.

Moving on to news from stocks in the FMCG space. GSK Consumer Healthcare share price is among the top losers on the bourses today.

The selloff came amid news that the company is looking to put iconic Horlicks for sale.

According to a leading financial daily, British pharmaceutical company GlaxoSmithKline plc will assess its Indian consumer healthcare subsidiary as it looks to fund a $13 billion buyout of Novartis' stake in their global consumer healthcare joint venture.

This is part of a 'strategic review' of consumer nutrition products that may include the sale of Horlicks, for which India is a big market.

It is not clear whether this assessment means that GSK plc would dilute its 72.5% stake in the subsidiary, GSK Consumer Healthcare. Horlicks Ltd held 43.16% stake in GSK Consumer Healthcare Ltd as of December 2017.

The combined sales of Horlicks and other nutrition products were approximately £550 million in 2017, GSK said in its statement. Nearly 85-90% of total Horlicks sales come from the India market. Besides India, GSK sells Horlicks in Sri Lanka and Bangladesh.

GSK expects the outcome of the strategic review to be concluded around the end of 2018, the company stated in a global release. It added that there can be no assurance that the review process will result in any transaction.

According to GSK, the company will increase focus on OTC and oral health categories. This portfolio includes Sensodyne toothpaste, Eno antacid, Panadol headache tablets, muscle gel Voltaren and Nicotinell patches, among others.

At the time of writing, GSK Consumer share price was trading down by 9%.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

Read the latest Market Commentary

What else is happening in the markets today? Dig in...

Equitymaster requests your view! Post a comment on "Sensex Continues Downtrend; GSK Consumer Down 9%". Click here!


Stock Market Updates

J&K BANK Share Price Up by 8%; BSE BANKEX Index Up 2.8% (Today's Market)

Mar 3, 2021 03:35 PM

J&K BANK share price is trading up by 8% and its current market price is Rs 32. The BSE BANKEX is up by 2.8%. The top gainers in the BSE BANKEX Index are J&K BANK (up 7.6%) and RBL BANK (up 5.2%).

RELIANCE IND. Share Price Up by 5%; BSE OIL & GAS Index Up 1.3% (Today's Market)

Mar 3, 2021 03:27 PM

RELIANCE IND. share price is trading up by 5% and its current market price is Rs 2,216. The BSE OIL & GAS is up by 1.3%. The top gainers in the BSE OIL & GAS Index is RELIANCE IND. (up 5.1%). The top losers are PETRONET LNG (down 0.1%) and BPCL (down 0.4%).

AU SMALL FINANCE BANK at All Time High; BSE BANKEX Index Up 2.8% (Today's Market)

Mar 3, 2021 03:23 PM

AU SMALL FINANCE BANK share price has hit an all time high at Rs 1,224 (up 4.2%). The BSE BANKEX Index is up by 2.8%. Among the top gainers in the BSE BANKEX Index today are AU SMALL FINANCE BANK (up 4.2%) and KOTAK MAHINDRA BANK (up 3.0%).

REDINGTON Share Price Down by 5%; BSE 500 Index Up 1.9% (Today's Market)

Mar 3, 2021 03:13 PM

REDINGTON share price is trading down by 5% and its current market price is Rs 200. The BSE 500 is up by 1.9%. The top gainers in the BSE 500 Index are IFCI (up 19.9%) and IDBI BANK (up 12.1%). The top losers are REDINGTON (down 5.1%) and SYMPHONY (down 5.1%).

RBL BANK Share Price Up by 5%; BSE BANKEX Index Up 2.7% (Today's Market)

Mar 3, 2021 03:09 PM

RBL BANK share price is trading up by 5% and its current market price is Rs 249. The BSE BANKEX is up by 2.7%. The top gainers in the BSE BANKEX Index are RBL BANK (up 5.0%) and FEDERAL BANK (up 5.7%).

Sensex Trades Over 500 Points Higher; Dow Futures Up by 147 Points (Today's Market)

Mar 3, 2021 12:30 pm

BSE Sensex is trading up by 586 points, while the NSE Nifty is trading up by 190 points.

View More Indian Share Market News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps(Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Make Rs 5,000 Per Day Trading the Market(Fast Profits Daily)

Feb 25, 2021

In this video, I'll show you how to get started on the path to daily trading profits.

I Believe the Investment of the Year Will Be...

Feb 19, 2021

In this episode, ace trader Brijesh Bhatia talks to us about the best investments of 2021, his profitable trading system, and much more.

The Hidden Tesla in My Great Indian Wealth Project(Profit Hunter)

Feb 23, 2021

An Indian company founded three decades ago in a garage caught my attention...


India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms


Mar 3, 2021 (Close)